A New Line of Sight Into

Targeted Cancer Therapies

Developing a Novel Class of Targeted
Alpha-Particle Radiopharmaceuticals

A New Line of Sight Into Targeted Cancer Therapies

Developing a Novel Class of Targeted
Alpha-Particle Radiopharmaceuticals

We are an alpha-particle radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents.

Our new, proprietary class of theranostics enable the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

We are an alpha-particle radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents.

Our new, proprietary class of theranostics enable the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

Theranostics:

Understanding Which Patients Will Respond to Therapy

See the Tumor – Determine patient response, image tumor and identify tumor location

Treat the Tumor – Demonstrated to kill cancer cells with the ability to optimize patient dosing based on diagnostic images

Theranostics:

Understanding Which Patients Will Respond to Therapy

See the Tumor – Determine patient response, image tumor and identify tumor location

Treat the Tumor – Demonstrated to kill cancer cells with the ability to optimize patient dosing based on diagnostic images

Development Pipeline

Development Pipeline

Get Notified:

Let us keep you up to date on news and information

Contact Us:

Viewpoint Molecular
Targeting, Inc.
2500 Crosspark Rd
Coralville, IA 52241
info@viewpointmt.com
(319) 665-2150

Investor Relations
JTC Team, LLC
Jenene Thomas
viewpoint@jtcir.com
(833) 475-8247